CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

Dr. Soren Thestrup-Nielsen M.D Joins Mainz Biomed's Strategic Advisory Board

Life Sciences Review Life Sciences Review | Friday, December 03, 2021
Tweet

As a member of the Strategic Advisory Board, Dr. Soren Thestrup-Nielsen will participate actively in the company’s product development and commercial strategies.


Fremont, CA: "It's a pleasure to welcome Soren to our newly formed Strategic Advisory Board as he brings us tremendous leadership in all aspects of a product's life cycle, commented Guido Baechler, Chief Executive Officer of Mainz Biomed. Dr. Soren Thestrup-Nielsen M.D. has joined the Strategic Advisory Board of Mainz Biomed N.V., a molecular genetics diagnostic company focusing on early cancer detection.  "All of us at the company are excited to work with Soren as we embark on ColoAlerts commercial roll-out across Europe and develop the regulatory and clinical strategy for the U.S. market." added, Baechler.


Dr. Thestrup-Nielsen has worked in the medical device sector for over 25 years, first at Boston Scientific and then at Danaher Corporation, where he supervised Danaher's acute care and laboratory diagnostics portfolio's inorganic growth.


He has held a number of notable executive positions in the past, including Chairman of Althea Group and member of the board of directors of a number of firms, including lung cancer screening startup Oncimmune. Dr. Thestrup-Nielsen has worked with medical enterprises in both North America and Europe on IPOs, trade sales, acquisitions, and a range of investment transactions. He earned his M.D. from the University of Copenhagen School of Medicine, worked as a general and vascular surgeon for five years, and earned an MBA from the IMD in Lausanne, Switzerland.


Dr. Thestrup-Nielsen will play an active part in the creation of the Company's product strategy for Europe, the United States, and the rest of the world, including clinical development, market segmentation, go-to-market strategy, and regulatory strategy, in his advisory capacity with Mainz Biomed. He'll also advise on the creation of the worldwide commercial strategy and the clinical plan for future versions of Mainz Biomeds' ColoAlert test, as well as lead the clinical advisor's board once it's established.


Weekly Brief

loading
Top 10 Biotech Startups Companies - 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/dr-soren-thestrupnielsen-md-joins-mainz-biomed-s-strategic-advisory-board-nwid-656.html